| Name | Company | P/L % | MPV |
|
|---|---|---|---|---|
| Lord Glendonbrook |
|
Stryker / NYQ:SYK | 323.84% | £296,688.29 |
| Lord Glendonbrook |
|
Abbott Laboratories / NYQ:ABT | 244.37% | £241,060.54 |
| Lord Sassoon |
|
Abbott Laboratories / NYQ:ABT | 164.47% | £185,127.65 |
| Lord Grabiner |
|
Boston Scientific / NYQ:BSX | 138.22% | £166,757.37** |
| Baroness Noakes |
|
Smith & Nephew / NYQ:SNN | 43.23% | £100,260.28 |
| Lord Glendonbrook |
|
Smith & Nephew / NYQ:SNN | 32.93% | £93,054.46 |
| Lord Glendonbrook |
|
Medtronic / NYQ:MDT | 10.66% | £77,463.33** |
| Lord Mance |
|
Stryker / NYQ:SYK | 6.99% | £74,894.91 |
| Lord Howard of Rising |
|
Ekf Diagnostics / LSE:EKF.L | 5.16% | £73,609.96 |
| Lord Londesborough |
|
Abbott Laboratories / NYQ:ABT | -20.04% | £55,970.41 |
| Lord Sassoon |
|
Medtronic / NYQ:MDT | -22.64% | £54,155.01 |
| Lord Glendonbrook |
|
Align Technology / NMS:ALGN | -38.49% | £43,058.63 |
| Lord Kakkar | Cyte / NMS:CTKB | -55.35% | £31,251.50** | |
| Lord Browne of Madingley | Allurion / NYQ:ALUR | -79.46% | £14,380.66 |